TrialCompass™ TCL
Back to trials
RecruitingPriority 4 · Lower priorityNCT03501576

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

ClinicalTrials.gov

Plain-language summary

This trial is testing standard influenza (and/or COVID) vaccination to study immune responses for patients with various types of peripheral T-cell lymphoma (PTCL) at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Inactivated Influenza Vaccine (BIOLOGICAL): Given seasonal inactivated influenza vaccine IM

  • Inactivated Influenza Vaccine

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

NCT03501576

Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing standard influenza (and/or COVID) vaccination to study immune responses for patients with various types of peripheral T-cell lymphoma (PTCL) at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • See full trial listing for complete eligibility

What's being tested

Inactivated Influenza Vaccine (BIOLOGICAL): Given seasonal inactivated influenza vaccine IM

Drugs / treatments: Inactivated Influenza Vaccine

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 200 patients

Primary endpoint: Cohort 1: Percentage of subjects achieving seroprotection, defined as the percentage of subjects with a post-vaccination HI titer > 1:40; Percentage of subjects achieving seroconversion; Cohort 2: Efficacy (immune response of COVID vaccines at least 7 days after the second dose.; Cohort 3: Efficacy (immune response) of COVID vaccines at least 7 days after each booster vaccine dose.

Ages: 18 Years to —

Start date: 2018-04-06 | Est. completion: 2028-05-26

Locations

2 US sites · 2 total

Georgia

Contact

Andres Chang, MD, PhD | andres.chang@emory.edu | 404-778-3942

Sponsor: Emory University (OTHER)

Tags

All T-cell lymphomas · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT03501576

Prepared using TrialCompass (trialcompass.com) on August 2, 2026. For informational purposes only. Always discuss with your healthcare team.